Megan Kruse

690 total citations
30 papers, 444 citations indexed

About

Megan Kruse is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Megan Kruse has authored 30 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Megan Kruse's work include Advanced Breast Cancer Therapies (10 papers), Breast Cancer Treatment Studies (10 papers) and HER2/EGFR in Cancer Research (7 papers). Megan Kruse is often cited by papers focused on Advanced Breast Cancer Therapies (10 papers), Breast Cancer Treatment Studies (10 papers) and HER2/EGFR in Cancer Research (7 papers). Megan Kruse collaborates with scholars based in United States, India and Germany. Megan Kruse's co-authors include Jame Abraham, Mathew Thomas, Leticia Varella, G. Thomas Budd, Halle C. F. Moore, Alberto J. Montero, Xuefei Jia, Tamara A. Sussman, Holly L. Thacker and Guy R. Newell and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Megan Kruse

27 papers receiving 425 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Megan Kruse United States 11 248 175 144 113 58 30 444
Gian Paolo Spinelli Italy 15 190 0.8× 158 0.9× 131 0.9× 91 0.8× 132 2.3× 50 514
Ann Boguniewicz United States 10 219 0.9× 100 0.6× 207 1.4× 99 0.9× 131 2.3× 18 429
Abha Soni United States 10 290 1.2× 139 0.8× 107 0.7× 61 0.5× 134 2.3× 23 519
Zebing Liu China 13 190 0.8× 134 0.8× 125 0.9× 113 1.0× 249 4.3× 38 514
Giulia Tasca Italy 11 271 1.1× 81 0.5× 139 1.0× 107 0.9× 60 1.0× 26 502
Justine N. McCutcheon United States 11 304 1.2× 107 0.6× 99 0.7× 70 0.6× 204 3.5× 16 680
Chiara Catania Italy 9 166 0.7× 100 0.6× 123 0.9× 154 1.4× 43 0.7× 28 401
Jonathan Reichel United States 8 236 1.0× 85 0.5× 102 0.7× 211 1.9× 122 2.1× 18 492
Pritesh Trivedi United Kingdom 11 189 0.8× 83 0.5× 88 0.6× 44 0.4× 139 2.4× 20 402
Sandeep Reddy United States 8 222 0.9× 93 0.5× 138 1.0× 150 1.3× 159 2.7× 18 458

Countries citing papers authored by Megan Kruse

Since Specialization
Citations

This map shows the geographic impact of Megan Kruse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Megan Kruse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Megan Kruse more than expected).

Fields of papers citing papers by Megan Kruse

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Megan Kruse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Megan Kruse. The network helps show where Megan Kruse may publish in the future.

Co-authorship network of co-authors of Megan Kruse

This figure shows the co-authorship network connecting the top 25 collaborators of Megan Kruse. A scholar is included among the top collaborators of Megan Kruse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Megan Kruse. Megan Kruse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kruse, Megan, et al.. (2025). ASO Visual Abstract: Trends in the Management of Small HER2 Positive Breast Cancers. Annals of Surgical Oncology. 32(8). 5587–5587.
2.
Kruse, Megan, et al.. (2025). Trends in the Management of Small HER2-Positive Breast Cancers. Annals of Surgical Oncology. 32(8). 5510–5520.
3.
Johnson, Justin M., Halle C. F. Moore, Megan Kruse, et al.. (2024). Abstract PO2-17-12: Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC. Cancer Research. 84(9_Supplement). PO2–17. 1 indexed citations
4.
Kruse, Megan, et al.. (2024). Reimagining Deintensification for Low-Risk Breast Cancer. JCO Oncology Practice. 21(3). 323–332.
5.
Budd, G. Thomas, Justin M. Johnson, Halle C. F. Moore, et al.. (2023). Abstract 3035: Phase I trial of alpha-lactalbumin vaccine in high-risk operable triple-negative breast cancer. Cancer Research. 83(7_Supplement). 3035–3035. 3 indexed citations
6.
Kruse, Megan, Emily Nash Smyth, Lee Bowman, et al.. (2023). Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world. Breast Cancer Research and Treatment. 201(1). 105–115. 6 indexed citations
7.
Oesterreich, Steffi, Azadeh Nasrazadani, Jian Zou, et al.. (2022). Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer. JNCI Journal of the National Cancer Institute. 114(11). 1511–1522. 31 indexed citations
8.
Valente, Stephanie A., et al.. (2022). Inflammatory breast cancer and the importance of skin punch biopsy. The American Journal of Surgery. 225(3). 549–552. 5 indexed citations
9.
Budd, G. Thomas, Justin M. Johnson, Halle C. F. Moore, et al.. (2022). Phase I trial of an alpha-lactalbumin vaccine in patients with moderate- to high-risk operable triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 40(16_suppl). TPS1125–TPS1125. 5 indexed citations
10.
Shah, Chirag, Pat W. Whitworth, Stephanie A. Valente, et al.. (2022). Bioimpedance spectroscopy for breast cancer-related lymphedema assessment: clinical practice guidelines. Breast Cancer Research and Treatment. 198(1). 1–9. 25 indexed citations
11.
Kruse, Megan, Mona Patel, Jeffrey M. McManus, et al.. (2021). Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer. JCI Insight. 6(20). 15 indexed citations
12.
Moore, Halle C. F., Jame Abraham, Megan Kruse, et al.. (2021). Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors. Clinical Breast Cancer. 22(2). 143–148. 15 indexed citations
13.
Cocco, Daniela, et al.. (2021). Invasive Lobular Breast Cancer: Data to Support Surgical Decision Making. Annals of Surgical Oncology. 28(10). 5723–5729. 9 indexed citations
14.
Kruse, Megan, Irene Kang, Nusayba A. Bagegni, et al.. (2021). Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature. Oncology and Therapy. 10(1). 279–289. 4 indexed citations
15.
Varella, Leticia, Megan Kruse, Xuefei Jia, et al.. (2020). Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer. Clinical Breast Cancer. 21(3). 205–209. 18 indexed citations
16.
Varella, Leticia, Xuefei Jia, Megan Kruse, et al.. (2019). Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Research and Treatment. 176(2). 429–434. 54 indexed citations
17.
Thomas, Mathew, et al.. (2019). Invasive lobular breast cancer: A review of pathogenesis, diagnosis, management, and future directions of early stage disease. Seminars in Oncology. 46(2). 121–132. 89 indexed citations
18.
Kruse, Megan & Jame Abraham. (2018). Management of Chemotherapy-Induced Alopecia With Scalp Cooling. Journal of Oncology Practice. 14(3). 149–154. 26 indexed citations
19.
Santa‐Maria, Cesar A., Megan Kruse, Paola Raska, et al.. (2017). Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers. Breast Cancer Research and Treatment. 166(1). 179–184. 6 indexed citations
20.
Varella, Leticia, Jame Abraham, & Megan Kruse. (2017). Revisiting the Role of Bevacizumab in the Treatment of Breast Cancer. Seminars in Oncology. 44(4). 273–285. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gian Paolo Spinelli Breakdown of academic impact, for papers by Ann Boguniewicz Breakdown of academic impact, for papers by Abha Soni Breakdown of academic impact, for papers by Zebing Liu Breakdown of academic impact, for papers by Giulia Tasca Breakdown of academic impact, for papers by Justine N. McCutcheon Breakdown of academic impact, for papers by Chiara Catania Breakdown of academic impact, for papers by Jonathan Reichel Breakdown of academic impact, for papers by Pritesh Trivedi Breakdown of academic impact, for papers by Sandeep Reddy
Rankless by CCL
2026